Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Blood (2012) 120 (21): 2590.

https://doi.org/10.1182/blood.V120.21.2590.2590

Published: 2012

Journal Articles

The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.

Masumi Ueda, M.D., Hu Xie, Ravinder K Sandhu, MD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Janis L. Abkowitz, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 2596.

https://doi.org/10.1182/blood.V120.21.2596.2596

Published: 2012

Journal Articles

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.

Laura F Newell, MD, Hu Xie, John M. Pagel, MD, PhD, Ravinder K Sandhu, MD, Pamela S Becker, MD, PhD, Roland B. Walter, MD, PhD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Janis L Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 2598.

https://doi.org/10.1182/blood.V120.21.2598.2598

Published: 2012

Journal Articles

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Joshua R. Veatch, MD, PhD, Ravinder K Sandhu, MD, Kathleen Shannon-Dorcy, RN, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1479.

https://doi.org/10.1182/blood.V120.21.1479.1479

Published: 2012

Journal Articles

The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia

Xueyan Chen, MD, PhD, Hu Xie, Carl Bohm, Brent L. Wood, MD, PhD, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, Ravinder K Sandhu, MD, Janis L Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1418.

https://doi.org/10.1182/blood.V120.21.1418.1418

Published: 2012

Journal Articles

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Mazyar Shadman, MD, MPH, Jack M. Lionberger, MD, PhD, Raya Mawad, MD, Ravinder K Sandhu, MD, Carol Dean, RN, Kathleen Shannon-Dorcy, RN, Kyle Wathen, PhD, Bart L Scott, MD, MS, Roland B. Walter, MD, PhD, Pamela S. Becker, MD, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 2622.

https://doi.org/10.1182/blood.V120.21.2622.2622

Published: 2012

NARROW

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Email alerts

ASH Publications

American Society of Hematology

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only